Table 2.

Adverse Events in Docosahexaenoic Acid (DHA) and Placebo Groups^a

	No. (%)
Adverse Event	DHA Group (n = 238)	Placebo Group (n = 164)	P Value
Any adverse event	214 (89.9)	144 (87.8)	.52
Diarrhea	18 (7.6)	10 (6.1)	.69
Urinary tract infection	23 (9.7)	12 (7.3)	.47
Fall	42 (17.6)	33 (20.1)	.60
Dizziness	12 (5.0)	9 (5.5)	.82
Agitation	24 (10.1)	12 (7.3)	.38
International normalized ratio
Decreased	3 (1.3)	0	NAb
Increased	0	1 (0.6)	NAb
Serious adverse eventsc
Any	76 (31.9)	50 (30.5)	.83
Hospitalization	67 (28.2)	43 (26.2)	.73
Death	11 (4.6)	4 (2.4)	.29
Deep venous thrombosis or pulmonary embolus	8 (3.4)	2 (1.2)	.32

^aIncludes adverse events occurring in at least 5% of participants, warfarin-associated adverse events of interest, all serious adverse events, and thrombosis-associated adverse events of interest.

^bUnable to calculate because of zero value.

^cDefined as events that result in death, hospitalization, prolongation of hospitalization, or are life threatening (based on the judgment of the study physician).